137 related articles for article (PubMed ID: 15203296)
1. Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders?
Evans KR; Sills T; Wunderlich GR; McDonald HP
J Psychiatr Res; 2004; 38(4):437-44. PubMed ID: 15203296
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
4. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
5. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
7. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.
Khan A; Brodhead AE; Kolts RL; Brown WA
J Psychiatr Res; 2005 Mar; 39(2):145-50. PubMed ID: 15589562
[TBL] [Abstract][Full Text] [Related]
8. A comparison of placebo responders and nonresponders in subgroups of depressive disorder.
Bialik RJ; Ravindran AV; Bakish D; Lapierre YD
J Psychiatry Neurosci; 1995 Jul; 20(4):265-70. PubMed ID: 7647079
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
10. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
14. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial.
Feltner D; Hill C; Lenderking W; Williams V; Morlock R
J Psychiatr Res; 2009 Oct; 43(15):1224-30. PubMed ID: 19423131
[TBL] [Abstract][Full Text] [Related]
15. Symptoms of anxiety in depression: assessment of item performance of the Hamilton Anxiety Rating Scale in patients with depression.
Vaccarino AL; Evans KR; Sills TL; Kalali AH
Depress Anxiety; 2008; 25(12):1006-13. PubMed ID: 18800370
[TBL] [Abstract][Full Text] [Related]
16. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
Brannan SK; Mallinckrodt CH; Detke MJ; Watkin JG; Tollefson GD
J Psychiatr Res; 2005 Mar; 39(2):161-72. PubMed ID: 15589564
[TBL] [Abstract][Full Text] [Related]
17. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
Baldwin D; Bridgman K; Buis C
J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
[TBL] [Abstract][Full Text] [Related]
19. Placebo response and antidepressant clinical trial outcome.
Khan A; Detke M; Khan SR; Mallinckrodt C
J Nerv Ment Dis; 2003 Apr; 191(4):211-8. PubMed ID: 12695731
[TBL] [Abstract][Full Text] [Related]
20. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.
Khan A; Schwartz K; Kolts RL; Ridgway D; Lineberry C
Biol Psychiatry; 2007 Jul; 62(1):65-71. PubMed ID: 17141744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]